OBJECTIVES: To estimate the impact of immune reconstitution inflammatory syndrome (IRIS) on morbidity and mortality in patients starting highly-active antiretroviral therapy (HAART). METHODS: A retrospective cohort study of HIV-positive patients starting HAART was conducted at a tertiary care referral center in Mexico City. We estimated the incidence of IRIS, hospitalizations and death rates during the first 2 years of HAART. The relative risk of death (RR) and hospitalization for patients with IRIS were adjusted for relevant covariates using regression methods. RESULTS: During the 2-year follow-up period, 27% of patients developed IRIS (14 IRIS cases per 100 person-years). The relative risk of death among patients who developed IRIS was 3 times higher (95% confidence interval (CI) 1.19-7.65, p = 0.03). After adjusting for previous opportunistic infections we still observed a higher death rate among patients with IRIS (RR 2.3, 95% CI 0.9-5.9, p=0.09). An effect modification of IRIS over mortality was observed by previous opportunistic infection. CONCLUSIONS: IRIS-associated mortality is strongly confounded by previous opportunistic infection. Patients with AIDS who eventually developed IRIS had the highest risk of death at the 2-year follow-up.
OBJECTIVES: To estimate the impact of immune reconstitution inflammatory syndrome (IRIS) on morbidity and mortality in patients starting highly-active antiretroviral therapy (HAART). METHODS: A retrospective cohort study of HIV-positivepatients starting HAART was conducted at a tertiary care referral center in Mexico City. We estimated the incidence of IRIS, hospitalizations and death rates during the first 2 years of HAART. The relative risk of death (RR) and hospitalization for patients with IRIS were adjusted for relevant covariates using regression methods. RESULTS: During the 2-year follow-up period, 27% of patients developed IRIS (14 IRIS cases per 100 person-years). The relative risk of death among patients who developed IRIS was 3 times higher (95% confidence interval (CI) 1.19-7.65, p = 0.03). After adjusting for previous opportunistic infections we still observed a higher death rate among patients with IRIS (RR 2.3, 95% CI 0.9-5.9, p=0.09). An effect modification of IRIS over mortality was observed by previous opportunistic infection. CONCLUSIONS: IRIS-associated mortality is strongly confounded by previous opportunistic infection. Patients with AIDS who eventually developed IRIS had the highest risk of death at the 2-year follow-up.
Authors: Catherine C McGowan; Pedro Cahn; Eduardo Gotuzzo; Denis Padgett; Jean W Pape; Marcelo Wolff; Mauro Schechter; Daniel R Masys Journal: Int J Epidemiol Date: 2007-09-10 Impact factor: 7.196
Authors: Maria Cristina Marazzi; Giuseppe Liotta; Paola Germano; Giovanni Guidotti; A Doro Altan; Susanna Ceffa; Massimo Magnano San Lio; Karin Nielsen-Saines; Leonardo Palombi Journal: AIDS Res Hum Retroviruses Date: 2008-04 Impact factor: 2.205
Authors: Graeme Meintjes; Stephen D Lawn; Fabio Scano; Gary Maartens; Martyn A French; William Worodria; Julian H Elliott; David Murdoch; Robert J Wilkinson; Catherine Seyler; Laurence John; Maarten Schim van der Loeff; Peter Reiss; Lut Lynen; Edward N Janoff; Charles Gilks; Robert Colebunders Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: Richard M Novak; James T Richardson; Kate Buchacz; Joan S Chmiel; Marcus D Durham; Frank J Palella; Andrea Wendrow; Kathy Wood; Benjamin Young; John T Brooks Journal: AIDS Date: 2012-03-27 Impact factor: 4.177
Authors: Juan G Sierra-Madero; Susan Ellenberg; Mohammed S Rassool; Ann Tierney; Pablo F Belaunzarán-Zamudio; Alondra López-Martínez; Alicia Piñeirúa-Menéndez; Luis J Montaner; Livio Azzoni; César Rivera Benítez; Irini Sereti; Jaime Andrade-Villanueva; Juan L Mosqueda-Gómez; Benigno Rodriguez; Ian Sanne; Michael M Lederman Journal: Lancet HIV Date: 2014-11-01 Impact factor: 12.767
Authors: Laura W Musselwhite; Bruno B Andrade; Susan S Ellenberg; Ann Tierney; Pablo F Belaunzaran-Zamudio; Adam Rupert; Michael M Lederman; Ian Sanne; Juan G Sierra Madero; Irini Sereti Journal: EBioMedicine Date: 2016-01-14 Impact factor: 8.143
Authors: S Janssen; K Osbak; R Holman; S Hermans; A Moekotte; M Knap; E Rossatanga; M Massinga-Loembe; A Alabi; A Adegnika; C Meenken; M van Vugt; P G Kremsner; G Meintjes; T van der Poll; M P Grobusch Journal: Infection Date: 2017-03-27 Impact factor: 3.553
Authors: Maryline Bonnet; Elisabeth Baudin; Ilesh V Jani; Elizabete Nunes; François Verhoustraten; Alexandra Calmy; Rui Bastos; Nilesh B Bhatt; Christophe Michon Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Kimberly F Breglio; Caian L Vinhaes; María B Arriaga; Martha Nason; Gregg Roby; Joseph Adelsberger; Bruno B Andrade; Virginia Sheikh; Irini Sereti Journal: J Infect Dis Date: 2021-06-15 Impact factor: 5.226